Literature DB >> 12800476

Diabetic nephropathy.

Ralph Rabkin1.   

Abstract

As the epidemic of diabetes spreads so does the number of patients at risk for developing diabetic nephropathy, which occurs in 20% to 40% of all diabetic patients. Indeed, diabetes is the most common cause of end-stage renal disease (ESRD) in the United States, accounting for > 40% of patients starting renal replacement therapy each year. Unfortunately, the outcome for diabetic patients with ESRD is worse than that for nondiabetic patients because of comorbid conditions in the diabetic population. However, with early and intensive blood glucose and blood pressure control--including the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers--the development and progression of diabetic kidney disease can be slowed.

Entities:  

Mesh:

Year:  2003        PMID: 12800476     DOI: 10.1016/s1098-3597(03)90014-7

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  13 in total

1.  Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy.

Authors:  Marie-Luise Brezniceanu; Cara J Lau; Nicolas Godin; Isabelle Chénier; Alain Duclos; Jean Ethier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

2.  Resveratrol: Evidence for Its Nephroprotective Effect in Diabetic Nephropathy.

Authors:  Vemana Gowd; Qingzheng Kang; Qi Wang; Qiang Wang; Feng Chen; Ka-Wing Cheng
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 3.  Diabetic nephropathy: Is it time yet for routine kidney biopsy?

Authors:  Maria L Gonzalez Suarez; David B Thomas; Laura Barisoni; Alessia Fornoni
Journal:  World J Diabetes       Date:  2013-12-15

Review 4.  Diabetic kidney disease: world wide difference of prevalence and risk factors.

Authors:  Osama Gheith; Nashwa Farouk; Narayanan Nampoory; Medhat A Halim; Torki Al-Otaibi
Journal:  J Nephropharmacol       Date:  2015-10-09

5.  Impact of Diabetic Stress Conditions on Renal Cell Metabolome.

Authors:  Simon Lagies; Roman Pichler; Tillmann Bork; Michael M Kaminski; Kevin Troendle; Stefan Zimmermann; Tobias B Huber; Gerd Walz; Soeren S Lienkamp; Bernd Kammerer
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

6.  Efficacy of dialysis for the treatment of patients with diabetic nephropathy: Study protocol.

Authors:  De-Rong Shao; Yue Zhou
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  The Effects of Momordica balsamina Methanolic Extract on Kidney Function in STZ-Induced Diabetic Rats: Effects on Selected Metabolic Markers.

Authors:  Anelisiwe Siboto; Ntethelelo Sibiya; Andile Khathi; Phikelelani Ngubane
Journal:  J Diabetes Res       Date:  2018-06-13       Impact factor: 4.011

8.  Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

Authors:  Martin Haluzík; Alice Cheng; Dirk Müller-Wieland; Jukka Westerbacka; Zsolt Bosnyak; Felipe Lauand; Lydie Melas-Melt; Janaka Karalliedde; Julio Rosenstock; Geremia B Bolli
Journal:  Diabetes Obes Metab       Date:  2020-04-28       Impact factor: 6.577

9.  Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study.

Authors:  Maja Baretić; Vesna Kušec; Ivana Pavlić-Renar
Journal:  Diabetes Ther       Date:  2018-10-08       Impact factor: 2.945

10.  Clinical efficacy and safety of Chinese herbal medicine for the treatment of patients with early diabetic nephropathy: A protocol for systematic review and meta-analysis.

Authors:  Xiaomei Yang; Chenling Hu; Shengju Wang; Qiu Chen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.